ETNB - 89bio gains as UBS starts at Buy; cites upcoming data from Akero
2023-08-28 12:36:36 ET
More on Akero, 89bio, etc.
- Akero Therapeutics: An Assessment
- 89bio, Inc.: A Big Bet On NASH
- Akero Therapeutics: Marching On And Delivering Promising Results
- Akero gains 15% on potential of liver disease drug and weight loss therapy combo
- 89bio starts phase 3 of pegozafermin for high triglycerides
- 89bio gains 47% on topline data for NASH candidate
- Akero upgraded at Morgan Stanley on NASH prospects
For further details see:
89bio gains as UBS starts at Buy; cites upcoming data from Akero